FDA panel nixes Regeneron's Arcalyst for gout

Regeneron ($REGN) may not be able to aim Aracalyst at the lucrative gout market. The would-be indication was shot down in an FDA advisory committee meeting, putting a new approval in doubt. Arcalyst is already marketed for a rare genetic disorder. Report